Allena Pharmaceuticals is focused on treating complex metabolic conditions that can lead to significant and costly health complications. The Company aims to reduce the burden of toxic metabolites such as oxalate and uric acid. These metabolites are normal byproducts of cellular activity and are also derived from the typical diet. In certain circumstances, they can build up and lead to complications such as hyperoxaluria and kidney stones (nephrolithiasis) in the case of oxalate, or hyperuricemia and gout in the case of uric acid.
Type
Private
HQ
Newton, US
Founded
2010
Size (employees)
40 (est)+3%
Allena Pharmaceuticals was founded in 2010 and is headquartered in Newton, US
Report incorrect company information

Key People/Management at Allena Pharmaceuticals

Alexey Margolin

Alexey Margolin

CEO
Hugh Wight

Hugh Wight

Vice President of Technical Operations

Allena Pharmaceuticals Office Locations

Allena Pharmaceuticals has an office in Newton
Newton, US (HQ)
One Newton Executive Park, Suite 202
Show all (1)
Report incorrect company information

Allena Pharmaceuticals Financials and Metrics

Summary Metrics

Allena Pharmaceuticals's latest funding round in December 2015 was reported to be $53 m. In total, Allena Pharmaceuticals has raised $93 m
Show all financial metrics

Allena Pharmaceuticals Financials

USD

Net income (Q1, 2018)

(7.9 m)

EBIT (Q1, 2018)

(8 m)

Cash (31-Mar-2018)

86.4 m
Annual
USDFY, 2017

General and administrative expense

5.4 m

R&D expense

15.5 m

Operating expense total

21 m

Interest expense

443 k
Quarterly
USDQ1, 2018

General and administrative expense

2 m

R&D expense

5.9 m

Operating expense total

8 m

EBIT

(8 m)
Annual
USDFY, 2017

Cash

94.5 m

Current Assets

96 m

PP&E

127 k

Total Assets

96.2 m
Quarterly
USDQ1, 2018

Cash

86.4 m

Current Assets

87.3 m

PP&E

128 k

Total Assets

87.6 m
Annual
USDFY, 2017

Net Income

(21.7 m)

Depreciation and Amortization

73 k

Accounts Payable

199 k

Cash From Operating Activities

(21.1 m)
Quarterly
USDQ1, 2018

Net Income

(7.9 m)

Depreciation and Amortization

19 k

Accounts Payable

529 k

Cash From Operating Activities

(6.9 m)
USDY, 2018

Financial Leverage

1.2 x
Show all financial metrics
Report incorrect company information